Ganglioglioma Arising from the Septum Pellucidum

Bishal Shrestha¹ Pritam Gurung¹ Sudan Dhakal¹ Pravesh Rajbhandari¹ Ranga Bahadur Basnet² Basant Pant¹

¹Department of Neurosurgery, Annapurna Neurological Institute and Allied Sciences, Maitighar, Kathmandu, Nepal
²Department of Neuropathology, Annapurna Neurological Institute and Allied Sciences, Maitighar, Kathmandu, Nepal


Abstract

A 24-year-old gentleman presented to us with complaints of occasional headache for 2 years. Magnetic resonance imaging showed enhancing supra sellar mass with nonenhancing cystic components, extending superiorly up to the body of bilateral lateral ventricle, laterally displacing septum pellucidum, and compressing the third ventricle with obstructive hydrocephalus. Hormone profile depicted adrenocorticotropic hormone <5.00 pg/mL, growth hormone 1.32 ng/mL, insulin-like growth factor-1 <3.0 ng/mL. The patient underwent surgical resection. Histological finding was suggestive of ganglioglioma World Health Organization grade I. Customized immunohistochemistry panel was advised and revealed positive CD 56, NSE, and GFAP immunohistochemical stains. Gangliogliomas are less frequent neoplastic lesions confined to only a handful of case reports and studies. Accounting less than 2% of intracranial neoplasms, these lesions primarily affect those in the first 3 decades of their life. As ubiquitous it is in nature, we hereby present a case of ganglioglioma in a young adult male arising from septum pellucidum.

Keywords

- ganglioglioma
- septum pellucidum
- brain neoplasm

Introduction

Gangliogliomas are World Health Organization Grade I, well-differentiated, benign tumor of glioneuronal origin.¹,² Perkins, in 1926, was the first to coin the term ganglioglioma. Documented to comprise 3% of all primary brain neoplasms, demographic studies have shown that this tumor primarily affects children and young adult with male sex preponderance (male:female: 1.9:1) and peak age of occurrence at 11 years.³ Despite being an omnipresent entity, most of these lesions are supratentorial, affecting the temporal lobes (>70%), in the basal diencephalon; the hypothalamus and within the vicinity of its slit-like cerebrospinal fluid cavity; and the third ventricle or the frontal lobes.¹,⁴ However, they are found to rarely involve the brainstem. The most common mode of presentation is seizure or change in the pattern of preexisting seizure activity which are usually refractory to pharmacotherapy. Other neurological manifestations are based on the site of the neoplasm. Following a complete resection, this is associated with a favorable 10-year survival rate as high as 82 to 93%.³

Only a few cases of intraventricular ganglioglioma have been reported making it a rare entity. As scarce is the lesion, septum pellucidum gangliogliomas are so few and far between that there are only three cases described as of...
now,5–7 and we report a clinical vignette in a patient who underwent complete surgical resection of the tumor.

**Case Report**

A 24-year-old gentleman showed up to our institution who had the chief condition of occasional headache for 2 years. It was gradual in onset, involving the bilateral temporal region, mild in intensity, on and off recurring every 3 to 4 days, without any aggravating or relieving factors. It then increased in severity and became continuous in nature for 15 days. Later, it was followed by blurring of vision of right eye. General examination revealed angiofibromas involving his face, ear lobules, nape of the neck, and shagreen patches over his lower back. Examination of visual acuity revealed loss of temporal vision of his right eye. Rest of the neurological examinations was unremarkable.

Magnetic resonance imaging (MRI) scan of the brain demonstrated T1/T2 isointense avidly enhancing suprasellar space occupying lesion with nonenhancing cystic components, extending superiorly up to the body of bilateral lateral ventricle, laterally displacing septum pellucidum and compressing the third ventricle with obstructive hydrocephalus (►Fig. 1A–C). Hormone profile depicted adrenocorticotropic hormone <5.00 pg/mL, growth hormone 1.32 ng/mL, and insulin-like growth factor-1 <3.0 ng/mL.

Bicoronal craniotomy, interhemispheric transventricle transeptal strategy, and gross total surgical clearance of the tumor in piecemeal were achieved (approximately 4 cm × 4 cm × 3 cm, soft to firm in consistency, and moderately vascular lesion involving the anterior horn of right ventricle lateralis encroaching into septum pellucidum and floor of the third ventricle with heterogeneous tissue architecture containing cystic masses in the contralateral ventricle).

Histopathological examination was suggestive of ganglioglioma with dysplastic ganglion cells in a disorganized pattern and clustering in a fibrillary background. Few of these cells have cytomegaly and pleomorphism with prominent nucleoli. Astrocytic component showed increased cellularity. Brightly eosinophilic round granular bodies of variable size and Rosenthal fibers, which are elongated “cork screw” eosinophilic intracellular inclusions, are also seen (►Fig. 2A,B).

Customized immunohistochemistry panel was advised and revealed immunoreactive CD 56, NSE, and GFAP suggestive of gangliogliotic cells and Ki-67 immunoreactive in only 1 to 2% of lesional cells suggestive of benign morphology (►Fig. 3).

The postoperative course was uneventful and the patient improved with no neurological deficits. The patient was discharged on 10th day in an ambulatory state with no neurological deficits.

**Discussion**

It dates back to early 19th century when the general rule for applying a new label to a newly identified growth must fulfill the criteria that it should be able to explain the etiology, describe its location, its histological features, or, preferably, its histogenesis. The nomenclature of ganglioglioma has
Courville provided a review of 20 cases of ganglioglioma. \( \text{cases} \) aged 29 years. The duration of symptoms was found to range from 3 months to 45 years of age (mean age: 11 years) by the time the patient presented for surgical intervention. 

The preferred treatment resort for ganglioglioma is surgery, the extent of resection depending upon intraoperative circumstances. Surgery is the greatest predictor of prognosis. Outcomes in the form of complete resolution of symptoms, partial improvement of symptoms, and death have been reported with surgical intervention. In those ineligible for complete resection due to tumor geography and potential hazardous neurological deficit following surgery, gamma knife radiosurgery is considered as an alternative. 

Gangliogliomas appear as a hypodense lesion in computed tomography (CT) scan with variable degrees of enhancement and foci of calcifications. The pattern of enhancement may be seen either in the form of homogeneous or inhomogeneous enhancement. Rarely, the tumor may not be visible at all even in a contrast-enhanced CT.

In a MRI, gangliogliomas have a multitude of appearances. Approximately 20 to 40% appear hypointense while 40 to 70% are isointense in T1-weighted MRI. Likewise, in T2-weighted MRI, they appear isointense in 20 to 30% and hyperintense in 70 to 90%.

Based on an imaging alone, a conclusive diagnosis of intraventricular ganglioglioma cannot be made. Presurgical possibilities such as ependymoma, subependymoma, astrocytoma, choroid plexus papilloma, germ cell tumor, neurocytoma, and metastasis should be considered in the list of differential diagnoses.

**Conclusion**

We have presented a very rare case of ganglioglioma arising from the septum pellucidum. Definite diagnosis prior to histopathological examination based on clinical and radiological features is often fallacious. It is therefore necessary to do a histopathological study and immune histological analysis to corroborate the diagnosis. Complete resection, if achieved, has a better prognosis in terms of progression-free survival.

**Conflict of Interest**

None declared.

**References**

8 Courville CB. Ganglioglioma: Tumor of the central nervous system; review of the literature and report of two cases. Arch Neurol Psychiatry 1930;24(03):439–491